Complex Innovative Design
Decentralized Clinical Trials
European Medicines Agency
Hybrid Clinical Trials
In-Vitro Diagnostic Regulation
Outsourcing Clinical Trials
Real-World Evidence (RWE)
Research & Development
Research and Development
Robotic-Assisted Surgery (RAS)
RWE Decision Alert
Opportunities and Challenges in the Therapeutic and CDMO Markets
Our Transaction Advisory experts have analyzed the CDMO industry trends, M&A activities, and projected growth in this CHEManager article.
The EU Pharmaceutical Package: Impact on Orphan Medicinal Products
This article reviews the proposed changes in the EU Pharma Package for data protection related to orphan medicinal products (OMPs).
Improving Access to Medicine: The Role of Pharma Companies in Emerging Markets
Our Market Access experts have identified risks and opportunities associated with improving access to medicines in emerging countries.
The EU Pharmaceutical Package: Regulatory Protection Changes
Our regulatory experts present a more detailed analysis of the proposed changes introduced to Regulatory Data Protection (RDP).
The EU Pharmaceutical Package: Introduction to Changes
Alira Health’s Regulatory experts explore how the proposed package will disrupt the European regulatory landscape and what it means for companies.
Lifecycle Optimization: A Checklist for Commercial Success
Download this checklist to get started with your successful commercial strategy and optimize the lifecycle of your product.
Outlook 2023: Firms Prepare For ‘World Where Health Care Has No Limits’
In the latest publication by Medtech Insights by Pharma Intelligence, executives at top device companies and other stakeholders share their expectations.
The State of Biopharma Funding
We spoke with Joris Pezzini, Executive Vice President of Biopharma, Alira Health, during the J.P. Morgan Healthcare Conference in San Francisco, which brings together investors and(...)
Debate sobre los IPT en oncología: buscando puntos de mejora en la evaluación y acceso de los fármacos oncológicos en España
For our Spanish community members, we are glad to share the Debate on IPT in oncology: Looking for points of improvement in the evaluation and access of oncological drugs in Spain.
FDA Project Orbis and Delivery of New Oncology Drugs to Market
Are you developing an oncology drug? Project Orbis, a program coordinated by the U.S FDA, allows you to register your product in several countries with a single submission. Find out(...)
An Insider Look at Vaccines: Yesterday, Today, Tomorrow
The COVID-19 pandemic has put vaccines in the spotlight. The pandemic has given the industry a considerable boost, and with lessons learned during the development and roll-out(...)
EU Supply Integrity Guidelines
Best practices for European supply integrity distribution and management as highlighted by Alira Health’s internal experts.
Infographic: 2021 Trends in Healthcare
It is no secret that the COVID-19 pandemic has presented new challenges for businesses, and virtual has become the ‘new normal’, including for transactions.
WHO Guideline: Recommendations on Pharma Pricing Policies
Alira Health’s market access experts dive into the WHO recommendations and provide advice on how companies can brace for impact.
Our Parallel Trade Expertise
Alira Health is proud to announce our new collaboration with Mark Inigo Jones, an industry leader in European parallel trade of pharmaceutical products.
Pre-Commercial Value Assessment of a Nuclear Medicine Pair to Diagnose and Treat Neuroendocrine Tumors (NET)
When our client, a leading radiopharmaceutical company, needed support to understand the commercial opportunity represented by a Phase III radiopharmaceutical and its diagnostic radiotracer(...)
In-Licensing Opportunity Assessment in a Subsegment of Anticoagulant Agents for the EU-5 Market
When our client, a renowned European pharma company, was interested in an in-licensing opportunity to drive its future growth while achieving significant commercial synergies, Alira(...)
Corporate Strategy for a Biotech Company with a Diversified Portfolio
When our client, a leader in the biopharmaceuticals space, needed support to assess their company’s competitive position and determine areas of growth and focus, the Alira Health(...)
Latest from Alira Health
The 2024 Global Medtech Contract Manufacturing Report: Executive Summary
The Importance of Involving Patients in the Health Technology Assessment Process for Rare Diseases
Experts Annabel de Maria and Ahmad Bechara share how engaging rare disease patients in the HTA process gives them the opportunity to have a meaningful impact.
Biopharma in 2024: The Industry Outlook
Insights from recent J.P. Morgan Healthcare Conference including what's changed in biopharma since last year and what to expect this year.
Pharma Company Succeeds in Adding Medicine to World Health Organization Essential Medicines List
A pharma company with a blood disorder treatment needed support to submit a value dossier to the WHO to add a medicine to the Essential Medicines List.
Pharma Company Extends to New Markets through Strategic Licensing Agreements
A Swedish pharma company saw a market opportunity to expand access to its proprietary product outside of the Nordics and sought support developing strategic licensing deals.
Pharma Develops e-Health Solution That Prioritizes Patients’ True Unmet Needs
A leading pharma company in the respiratory market sought support developing the right digital platform to expand their patient base and increase retention.
Connect with our biotech experts onsite in Barcelona at Bio-Europe Spring. How can we support your development plan and funding path?
XXII Conferenza Nazionale Sulla Farmaceutica
Meet Giovanni Firenze, Partner Consulting Italy, onsite in Catania and learn more about the impact of the new AIFA reform.
World EPA Congress Europe
Look for market access and pricing experts Ahmad Bechara and Andrea Mantovani representing Alira Health on the agenda at World EPA Congress.
Robotic-assisted Surgery in Orthopedic Procedures: Current Landscape and 2024 Outlook
What Comes After the mRNA Vaccines?
In the third episode of VacciTalks, we’ll discuss these new alternatives to mRNA vaccines and the promise they hold.
Medtech CDMO: Market and M&A Global Trends in 2024
This webinar replay investigates the current state of the global medtech CDMO industry and highlight Europe as a promising frontier for consolidation.
Alira Health Releases The 2024 Global Medtech Contract Manufacturing Report
Alira Health announced the release of the 2024 Global Medtech Contract Manufacturing Report. This report offers a comprehensive analysis of trends in the global medtech contract manufacturing(...)
Alira Health Advises Aesculapius Farmaceutici Srl in Its Acquisition by Ceres Pharma NV
We are pleased to have represented as transaction advisor Aesculapius, a leading Italian pharmaceutical company active in the development and distribution of prescription drugs, OTC(...)
Alira Health Releases Global Report on Robotic-Assisted Surgery (RAS) in Orthopedic Procedures
New analysis reveals the RAS in Orthopedics market is anticipated to grow 10% annually over the next five years, reaching more than 2.5 million procedures in the EU, UK and US.
Best Practices for Health Technology Assessment of Robotic Assisted Surgery
An expert panel developed seven best-practice recommendations for evaluating Robotics Assisted Surgical systems and here are the results.
Therapeutic IgG-Like Bispecific Antibodies: Modular Versatility and Manufacturing Challenges
Our experts conducted a deep evaluation of IgG-like bsAbs including general advantages and disadvantages compared with MAbs and more.
Immunoglobulin Fc-Fusion Proteins
Our experts published a series of articles in BioProcess International reviewing the state of the art of Fc – fusion proteins, including their structure and molecular design, manufacturing(...)